Olaparib 150 mg is a targeted therapy medication belonging to the class of drugs known as PARP inhibitors (Poly ADP-Ribose Polymerase inhibitors). It is commonly prescribed for treating certain types of cancers, such as ovarian, breast, pancreatic, and prostate cancers, that are linked to mutations in the BRCA1 or BRCA2 genes.

Olaparib targets and inhibits the PARP enzyme, which plays a role in DNA repair. Cancer cells with defective BRCA genes rely heavily on PARP for survival. By blocking PARP, Olaparib prevents the repair of damaged DNA in cancer cells, causing them to die while sparing normal cells.

Dosage & Administration

Recommended Dose:

300 mg daily, divided into two doses of 150 mg each.

Should be taken with or without food, as per your doctor’s advice.

Duration:

Treatment duration depends on your medical condition and response to therapy.

Missed Dose:

If you miss a dose, skip it and continue with your next dose. Do not double the dose.

1. Improves progression-free survival in cancer patients.
2. Reduces the risk of cancer recurrence.
3. Offers a targeted approach, minimizing damage to healthy cells.
4. Effective in patients with BRCA mutations.

Possible Side Effects

Common Side Effects:

Nausea

Fatigue

Vomiting

Anemia (low red blood cell count)

Decreased appetite

Serious Side Effects:

Bone marrow suppression

Risk of developing secondary cancers such as leukemia or myelodysplastic syndrome (MDS)

Lung inflammation (pneumonitis)

When to Seek Medical Attention:

Persistent fatigue, shortness of breath, unexplained bruising, or bleeding.

Pregnancy:

Avoid during pregnancy, as Olaparib can harm an unborn baby. Use effective contraception during treatment.

Breastfeeding:

Not recommended while taking Olaparib.

Kidney Function:

Dose adjustment may be required in patients with impaired kidney function.

Interactions:

Avoid grapefruit or grapefruit juice as it can interfere with the medication’s efficacy.

Inform your doctor about all medications you are taking to avoid interactions.